• Home

  • Partners

  • Work Packages

  • News and Events

  • Intranet

  • Contact Us

  • Glossary

  • More

    SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools

    Participants

     

    • Boehringer Ingelheim

    • Lund University

    • Biocomputing Platforms Ltd

    • Karolinska Institute

    • Helmholtz Zentrum Muenchen, Deutsches Forschungszentrum fur Gesundheit und Umwelt 

    • Instituto di Ricerche Farmacologiche “Mario Negri”, Bergamo

    • University of Dundee

    • Folkhälsan, Helsinki 

    • The National Institute for Health and Welfare, Finland

    • University of Eastern Finland

    • University of Oxford

    • Pfizer limited

    Navigation

    • Work Package (WP1)

    • Work Package (WP2)

    • Work Package (WP3)

    • Work Package (WP4)

    • Work Package (WP5)

    • Work Package (WP6)

    • Project Partners

    Genetic markers for diabetes complications

    • Integrating genome-wide association (GWA) data provided by partners and collaborators with SUMMIT-funded GWA studies in new samples from patients diagnosed for diabetes complications (ensuring maximal overlap with efforts in other WPs). ​Using high-throughput sequencing tecnhologies, SUMMIT completed the largest ever GWAS and generated nearly all the data for the first-ever exome sequencing study. 

     

    • E​stablishing a robust pipeline for handling the data generated by these projects and for ensuring timely and effective analysis. The combined efforts of WP1 participants are expected to contribute to the discovery of genetic markers that enable to assess the risks of diabetes complications and lead to the development of new therapeutic solutions. 

    Work Package 1 (WP1)

          WP1 aims at:

     

    • Identifying novel genetic markers that predict susceptibility to chronic diabetic complications.

     

    © 2014 by IMI-SUMMIT. All rights reserved.

    Website design: Klodiana Jani

    MISSION

    T​o DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:

    ​

    • the identification of patients at high risk of diabetes complications

    • the monitoring of the complications' progression and patients‘ response to therapy 

    ​

    To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.

    

    Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.

    Related Sites